Lorinda Chung, MD
Rheumatology · Palo Alto, CANPI 1427026442
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $32,435 of the $38,325 with a category attached, or 84.6%. 8 manufacturers reported payments, led by Boehringer Ingelheim at 51.4% of the total. Reporting peaked in 2019 at $14,666 and has fallen 78.2% since, to $3,200 in 2025.
Across 52 payments — averaging $737.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$20K
- Mitsubishi Tanabe Pharma Development America, Inc.$4K
- Boehringer Ingelheim International GmbH$4K
- Genentech, Inc.$3K
- AbbVie$2K
- Eli Lilly$2K
- plus $3K from 2 others
Across 95 payments — averaging $10,930 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$473K
- GSK$132K
- United Therapeutics Corporation$104K
- Amgen$97K
- Tanabe Pharma America, Inc.$86K
- Kadmon Corporation LLC$76K
- plus $71K from 4 others
What the payments were for
- Consulting fees$32,43585%
- Speaking & faculty fees$1,9135%
- Travel & lodging$2,9418%
- Food & beverage$1,0223%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 24 | $19,714 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 3 | $4,475 |
| Boehringer Ingelheim International GmbH | 6 | $4,234 |
| Genentech, Inc. | 6 | $3,200 |
| AbbVie | 3 | $2,433 |
| Eli Lilly | 1 | $1,600 |
| Actelion Pharmaceuticals US, Inc. | 1 | $1,550 |
| Amgen | 8 | $1,119 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,325 in reported general payments places this provider in the 85th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sildenafil Citrate | 27 | $2,006 |
| Hydroxychloroquine Sulfate | 22 | $1,149 |
| Escitalopram Oxalate | 12 | $152 |
| Prednisone | 17 | $96 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Palo Alto
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.